


Geographic atrophy

Geographic atrophy (GA) is a progressive, irreversible and blinding disease that tends to affect both eyes

GA is an **advanced form of age-related macular degeneration (AMD)**, which is estimated to affect over

5 million people WORLDWIDE^{1,2}

GA is characterised by one or more distinct dark patches on the retina, with corresponding areas of reduced vision or ‘blind spots’³



These dark patches represent the **death** of different cell types in the retina, including the **light-sensitive photoreceptors**⁴

GA has a devastating impact on the lives of people living with the disease

People with GA often have problems with



Reading



Driving




Shopping



Mobility⁵

People with GA report feelings of frustration and annoyance⁵

A third of people with advanced AMD have clinical depression⁶



A visual acuity test is used to assess GA

Unfortunately, visual acuity alone does not fully capture the functional impact of GA such as loss of reading ability, highlighting the need for improved testing



There are no approved treatments for GA

But strategies for management of AMD include



Low visual aids



Prevention with antioxidants + zinc⁷



Counselling

At present, several therapeutics are in clinical trial evaluation; however, with **no approved treatment**, GA represents a **significant unmet medical need**

References

1. Wong WL et al. Lancet Glob Health 2014; 2: e106–16
2. Rudnicka A et al. Ophthalmology 2012; 119: 571–80
3. Panorgias A et al. Invest Ophthalmol Vis Sci 2013; 26: 54: 4372–84
4. Biarnés M et al. Optom Vis Sci 2011; 88: 881–9
5. Hassell JB et al. Br J Ophthalmol 2006; 90: 593–6
6. Brody BL et al. Ophthalmology 2001; 108: 1893–901
7. AREDS Research Group. Arch Ophthalmol 2001; 119: 1417–36